

December 12, 2024

The Secretary Listing Department, BSE Limited, 1 st Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400001 Scrip Code: 540975	The Manager, Listing Department, The National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (East), Mumbai 400051 Scrip Symbol: ASTERDM
---	--

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 (“LODR Regulations”)

Ref: Update on disclosures made by Aster DM Healthcare Limited (“Company”) on March 28, 2022, June 11, 2022, November 10, 2022, February 14, 2023, July 05, 2023, July 24, 2023, November 28, 2023, December 23, 2023, December 30, 2023, January 12, 2024 and January 15, 2024

In relation to the reference given above and the transaction between Affinity Holdings Private Limited (“**Affinity**”) and Aster GCC Holdings Limited (erstwhile known as Alpha GCC Holdings Limited) for segregation of the Company’s GCC business (“**Transaction**”), we wish to inform you that:

- a) The Company has made an investment of USD 4,900,000 (United States Dollars Four Million Nine Hundred Thousand) in Affinity to enable Affinity to fulfil certain agreed payment obligations of Affinity under the Sale and Purchase Agreement dated November 28, 2023 entered between Affinity and Alpha GCC Holdings Limited (“**SPA**”), as amended by the First Deed of Amendment to SPA dated March 19, 2024 and Second Deed of Amendment to SPA dated April 01, 2024..
- b) As per the transaction terms disclosed earlier on January 15, 2024, a limited portion of the transaction proceeds were retained to meet the payment obligations (including pertaining to leakages and indemnities) of Affinity under the SPA. As on date, a payable amount of USD 4.34 million has been determined so far in terms of the SPA. These amounts are within the caps and limitations agreed under the SPA and will be paid by Affinity in compliance with the defined terms.

- c) The details of the said investment, as required under Regulation 30 read with Schedule III Part A Para A(1) of the Listing Regulations and SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed as **Annexure A**.

For Aster DM Healthcare Limited

Hemish Purushottam

Company Secretary and Compliance Officer

Annexure A

No	Particulars	Details
a)	Name of the target entity Details in brief such as size, Turnover etc	Affinity Holdings Private Ltd ("Affinity") Paid-up capital: Pre-Issue – USD 1,000 Post- Issue- USD 49,01,000 Turnover for FY 2023-24- USD 13.04 million
b)	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The current investment falls under the purview of the transaction with related parties under the Companies Act, 2013 and Regulation 23 of LODR Regulations. Affinity is a wholly owned subsidiary of Aster DM Healthcare Limited. The investment has been made at fair market value based on the independent valuation report as required under applicable law.
c)	Industry to which the entity being acquired belongs;	Affinity's principal activity is investment holdings.
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The investment is made to enable Affinity to fulfil its contractual obligations arising under the SPA read with the First Deed of Amendment and the Second Deed of Amendment. Company's shareholding post this investment remains at 100%.
e)	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable

No	Particulars	Details
f)	Indicative time period for completion of the acquisition;	The transaction is expected to complete on or before December 2024
g)	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration by way of remittance through normal banking channel.
h)	Cost of acquisition and/or the price at which the shares are acquired.	A total consideration of USD 49,00,000 (United States Dollars Four Million Nine Hundred Thousand) will be paid towards subscription of USD 49,00,000 (United States Dollars Four Million Nine Hundred Thousand) equity shares of face value USD 1/- each fully paid up.
i)	Percentage of shareholding / control acquired and / or number of shares acquired.	With the current investment, the Company's shareholding in Affinity remains at 100%.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>About the entity: Affinity was incorporated in the Republic of Mauritius on January 24, 2008 under the Mauritius Companies Act 2001.</p> <p>Line of Business: The principal activity of Affinity is to engage in investment holding.</p> <p>Turnover:</p> <p>FY 2021-22- USD 10.06 million FY 2022-23- USD 3.53 million FY 2023-24- USD 13.04 million</p>